{"nctId":"NCT00602420","briefTitle":"Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)","startDateStruct":{"date":"2008-06"},"conditions":["Musculoskeletal Complications","Pain","Unspecified Adult Solid Tumor, Protocol Specific"],"count":510,"armGroups":[{"label":"Naproxen","type":"EXPERIMENTAL","interventionNames":["Drug: naproxen"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: placebo"]}],"interventions":[{"name":"naproxen","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of a non-hematologic (non-myeloid) malignancy\n* Scheduled to receive chemotherapy; chemotherapy may be given for adjuvant, neoadjuvant, curative, or palliative intent\n* Scheduled to receive the first dose of pegfilgrastim (Neulasta®) to ameliorate chemotherapy-induced neutropenia\n* Creatinine ≤ 1.5 times upper limit of normal\n* Able to understand English\n* More than 6 months since prior surgery on the heart\n\nExclusion Criteria:\n\n* Pregnant or nursing\n* Clinical evidence of active gastrointestinal bleeding, prior gastrointestinal bleeding, or gastric or duodenal ulcers\n* Allergy to naproxen\n* Prior development of the triad of asthma, rhinitis, and nasal polyps after taking acetylsalicylic acid (aspirin) or other NSAIDs\n* Concurrent nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, or any product containing naproxen (e.g., Naprosyn, EC-Naprosyn, Anaprox, Anaprox-DS, Naprosyn suspension, or Aleve), on a regular basis\n* Concurrent steroids on a regular basis\n* Concurrent prescription or non-prescription medications for preexisting chronic pain; concurrent cardioprotective doses (≤ 325 mg/day) of aspirin allowed\n* Concurrent therapeutic doses of warfarin","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"120 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under Curve (AUC) of Average Pain From Diary vs. Day (1-5), Calculated by the Trapezoidal Rule.","description":"Severity and duration of bone pain (day 1 being the day pegfilgrastim is administered) as measured by a daily diary. Patients recorded daily pain (Pain Scale Score) severity on a scale of 0 (no pain) to 10 (pain as bad as you can imagine) for the last 24 hours. The AUC range was 0-40, and the units are (Pain Scale Score)\\*Days.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.04","spread":null},{"groupId":"OG001","value":"7.71","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":257},"commonTop":["Supraventricular tachycardia (SVT); Rash","Infection - right breast w/ cellulitis, normal ANC","Hyperglycemia","Anaphylactic reaction","Acute pain secondary to marrow expansion"]}}}